Scientific Program

OMICS Group Conferences
Accelerating Scientific Discovery

3rd World Congress on Cancer Science & Therapy

October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA



Media Partners

BENTHAM SCIENCE | ecancer | BioPortfolio | MEDtube
HORIZON bioadvance | 8TH INTERNATIONAL CANCER CONTROL CONGRESS | Senology Oncology and Women's Health | labroots Your Science Network

"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to *symposia@omicsonline.org*

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: *cancerscience-2013@omicsonline.net*

Day 1 October 21, 2013

07:00-08:30 **Registrations**

Sierra Ballroom

OMICS Group Conferences
Accelerating Scientific Discovery

08:30-09:00 **Opening Ceremony**

Keynote Forum

09:00-09:05 **Introduction**

09:05-09:30 **Stewart Sell**
Wadsworth Center, USA

09:30-09:55 **Michael Retsky**
Harvard School of Public Health, USA

09:55-10:20 **Jimmy T. Efird**
Brody School of Medicine, USA

Coffee Break 10:20-10:35 @ Sierra Foyer

Track 1: Cancer Therapy and Clinical Cancer Research

Session Chair: Stewart Sell, Wadsworth Center, USA

Session Co-Chair: Su-shing chen, University of Florida, USA

Session Introduction

10:35-10:55 **A Gene signature that predicts deficiency of homologous recombination DNA repair in cancer**
Shiaw-Yih (Phoebus) Lin, MD Anderson Cancer Center, USA

10:55-11:15 **Rationale-driven identification of novel gemcitabine sensitivity genes as biomarkers of outcome in pancreatic cancer patients by exploiting the replication stress response**
David S. Yu, Emory University School of Medicine, USA

11:15-11:35 **Targeting cellular survival responses to replication stress in cancer**
Guang Peng, MD Anderson Cancer Center, USA

11:35-11:55 **A novel role of 53BP1 in alternative non-homologous end joining**
Junran Zhang, Case Western Reserve University, USA

11:55-12:15 **Regulation of stemness gene expression and tumorigenicity by an endogenous matrix metalloproteinase inhibitor RECK**
Wen-Chun Hung, National Institute of Cancer Research,Taiwan

12:15-12:35 **Cancer susceptibilities revealed through a map of negative genetic interactions in isogenic cancer cells**
Jason Moffat, University of Toronto, Canada

12:35-12:55 **Role of the TMPRSS2-ERG gene fusion and autophagy in DNA damage and repair of prostate cancer**
Alexandru Almasan, Cleveland Clinic Foundation, USA

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15 **Identifying the molecular basis for PARP1 inhibition sensitivity in Ewinga™s sarcoma, potential for stratifying patients during clinical trials and implications for breast and ovarian cancer**
Alex Bishop, University of Texas Health Science Center, USA

14:15-14:35 **Ubiquitin signaling in response to DNA damage**
Chunying Du, University of Cincinnati College of Medicine, USA

14:35-14:55 **PARP1 roles in chromosomal translocations and DNA integration**
Jac A. Nickoloff, Colorado State University, USA

14:55-15:15 **A critical role of the SUMO pathway in KRAS-driven oncogenesis**
Ji Luo, National Cancer Institute, USA

15:15-15:35 **Cancer Applications of Multistage Nanovector Systems Based on Microfabricated Porous Silicon Particles**
Biana Godin-Vilentchouk, Houston Methodist Research Institute, USA

15:35-15:55 **Transarterial infusion chemotherapy for non-small cell lung cancer**
Masanori Nakanishi, General Nanto Hospital, Japan

15:55-16:15 **Recombinant immunotoxin targeting cancer specific surface antigen for cancer therapy**
Tapan K Bera, National Cancer Institute, USA

Coffee Break 16:15-16:30 @ Sierra Foyer

16:30-16:50 **Nutritional aspects in the treatment of head neck cancer patients**
Jens Buentzel, Suedharz Klinikum Nordhausen, Germany

16:50-17:10 **A synergistic strategy of cancer therapies: The scientific foundations and clinical opportunities**
Su-shing chen, University of Florida, USA

17:10-17:30 **Targeting early B-cell receptor signaling inducesapoptosis in leukemic mantle cell lymphoma**
Mohand-Akli Boukhiar, University of Paris, France

17:30-17:50	**A pre-clinical breast cancer stem cell model based on MMTV-PyMT mice for testing nanoparticle directed therapy** **Stewart Sell,** Wadsworth Center, USA
17:50-18:10	**Prevention of fibroblast senescence by hyaluronic acid and clinical application to chemoradiation-induced oral mucositis** **Nicola Cirillo,** The Universityof Melbourne, Australia
18:10-18:30	**The Rediscovery of UPI-928** **John Rothman,** Update Pharma Inc., USA
18:30-18:50	**Alteration of B-Cell Receptor (BCR) signaling in B-cell lymphomas: New therapeutic targets for lymphoma treatment** **Dominique Ledoux,** University of Paris, France
18:50-19:10	**Mucoadhesive Brazilian propolis gel for prevention of radiation-induced oral mucositis** **Vagner Rodrigues Santos,** Universidade Federal de Minas Gerais, Brazil
19:10-20:10	Cocktails Sponsored by **Journal of Cancer Science & Therapy @ Siersa Foyer**

Muir Woods

Track 2: Cancer Cell Biology, Diagnostic and Prognostic Cancer Biomarkers
Track 5: Advances in Cancer Detection, Imaging, Management & Prevention

Session Chair: Stephen J. Beebe, Old Dominion University, USA
Session Co-Chair: Sandip K. Mishra, Institute of Life Sciences, India

Session Introduction

10:35-10:55	**Nanosecond pulsed electric fieldsabolish orthotopic rat hepatocellular carcinoma and bypass cancer mutations that evade apoptosis induction** **Stephen J. Beebe,** Old Dominion University, USA
10:55-11:15	**Unraveling the story about the possible backups when estrogen receptor goes deregulated in breast cancer** **Sandip K. Mishra,** Institute of Life Science, Bhubaneswar, India
11:15-11:35	**Identification of new molecular markers for minimal residual disease assessment in acute leukemia patients** **Sona Pekova, Chambon,** Laboratory for molecular diagnostics, Czech Republic
11:35-11:55	**Cell signaling and tissue dynamics of tumor initiation from suppressive epithelial environments** **Cheuk T. Leung,** University of Minnesota, USA
11:55-12:15	**Cellular nanomechanics, a new drug sensitivity marker for ovarian cancer** **Shivani Sharma,** University of California, USA
12:15-12:35	**The Warburg effect and beyond** **Zhimin Lu,** The University of Texas, MD Anderson Cancer Center, USA
12:35-12:55	**Cancers and the Concept of Cell Senescence** **Alvaro Macieira-Coelho,** French National Institute of Health, France
	Lunch Break 12:55-13:55 @ Tiburon/ Sausalito
13:55-14:15	**Therapeutic efficacy of ^{188}Re-human serum albumin microspherein GP7TB hepatoma model via intraarterial route** **Liang-Cheng Chen,** Institute of Nuclear Energy Research, Taiwan
14:15-14:35	**Effects of Anti-obesity dietary supplement Dehydroepiandrosterone (DHEA) treatment on Serum methylation and oxidative stress biomarkers in DMBA-Induced Mammary Tumor Obese Zucker Rat Model** **Reza Hakkak,** University of Arkansas, USA
14:35-14:55	**The etiology of bladder cancer and its dietary remedy** **King-Thom Chung,** The University of Memphis, USA
14:55-15:15	**Psychoneuroendocrinoimmunology and cancer: Psychoimmunological evaluation and prognosis in cancer disease** **Giuseppina Messina,** International Integrative Medicine, Italy
15:15-15:35	**MDM2 modulates the cellular response to cdk4 inhibition** **Andrew Koff,** Memorial Sloan-Kettering Cancer Center, USA
15:35-15:55	**Asbestos cancer and biomarker HUNT** **Oluf Dimitri Roe,** Norwegian University of Science and Technology, Norway
15:55-16:15	**Human cancer is a parasite spread via intrusion in genome** **Sergey N. Rumyantsev,** Andent, Inc., USA
	Coffee Break 16:15-16:30 @ Sierra Foyer
16:30-16:50	**Cancer risk following CT-imaging: A Monte Carlo based study** **Johann Wanek,** University of Zurich, Switzerland
16:50-17:10	**McAb NJ001 plays the key role of immunodiagnosis and immunotherapy for NSCLC** **Shiyang Pan,** Nanjing Medical University, China
17:10-17:30	**Home Parenteral Nutrition in cancer and the suitability of prescribtion based on the duration of therapy** **Michela Zanardi,** ASLTO2 SAN Giovanni Bosco Hospital, Italy
17:30-17:50	**Paraganglioma and SDH mutation** **Fruhmann Johanna,** Medical University Hospital Graz, Europe
17:50-18:10	**Chronic low level arsenic may increase the risk of lung carcinogenesis: Role of inflammatory responses** **Dona Sinha,** Chittaranjan National Cancer Institute, India
18:10-18:30	**Fractal and euclidean geometrical diagnosis of cervix cytology** **Javier Rodríguez,** Insight Group - Fundación universitaria de Ciencias de la Salud, Colombia
18:30-18:50	**Fluorescence for diagnosis at point of care** **Aurelija Vaitkuviene,** Lithuania University, Lithuania
18:50-19:10	**Mexican medicinal plants used for cancer treatment** **Angel Josabad Alonso-Castro,** National Autonomous University of Mexico, Mexico
19:10-19:30	**Preclinical and clinical testing of a alpha-ketoglutarate/5-HMF/N-actyl-selenomethionine and N-acteyl-methionine for treating tumors** **Joachim Greilberger,** Medical University of Graz, Austria
19:30-20:30	Cocktails Sponsored by **Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer**

Day 2 October 22, 2013

Sierra Ballroom

Keynote Forum

08:30-08:55 **Sudhakar Akul Yakkanti**
Center for Cancer & Metabolism, Cell Signaling Laboratory, USA

08:55-09:20 **Sherry A. Bradford**
Accutheranostics Inc., USA

Workshop on "Animal models of cancer therapy"

09:20-09:40 **Animal Models of Human Cancer Vaccines**
Dorothee Herlyn, The Wistar Institute, USA

09:40-10:00 **PHD2 silencing cooperates with $BRaf^{V600E}$ to induce melanoma formation**
Xiaowei Xu, University of Pennsylvania School of Medicine, USA

10:00-10:20 **Mouse models as drivers in defining new targets for therapies - Examples from prostate cancer melanoma studies**
Ze'ev Ronai, Sanford-Burnham Medical Research Institute, USA

Coffee Break 10:20-10:35 @ Sierra Foyer

10:35-10:55 **Exploring The Response of BRAF or PIK3CA Mutated Cancers to Pathway-Targeted inhibition using Mouse models**
Martin McMahon, University of California, USA

10:55-11:15 **Patient derived xenograft models of melanoma as pre-clinical models for personalized medicine**
Clemens Krepler, The Wistar Institute, USA

11:15-11:35 **Hypoxia induces phenotypic plasticity in melanoma via the novel tyrosine kinase receptors ROR1 and ROR2**
Michael O'Connell, The Wistar Institute, USA

Track 3: Organ-Specific Cancers, Cancer Genetics, Drug Development and Diagnosticsy

Session Chair: Michael Retsky, Harvard School of Public Health, USA
Session Co-Chair: Yoshiaki Omura, New York Medical College, USA

Session Introduction

11:35-11:55 **Very high incidence of Carcinogenic Human Papilloma Virus Type 16 (HPV-16) was found with Chrysotile Asbestos, and HPV-18, with Tremolite Asbestos, was found in less than 10% in Human Breast Cancer Tissues: Their implications in diagnosis, treatment, and prevention of the Breast Cancer**
Yoshiaki Omura, New York Medical College, USA

11:55-12:15 **Merging experimental data and In silico analysis: A systems-level approach to cancer**
Nicola Cirillo, The University of Melbourne, Australia

12:15-12:35 **Micronucleus in exfoliated buccal mucosa cells of Mexican women with Breast Cancer**
Aurelio Flores-García, Autonomous University of Nayarit, Mexico

12:35-12:55 **The synthesis and pharmacological evaluations of tetrahydroisoquinolines (THIQs) as anti-breast cancer agents**
Kinfe Ken Redda, Florida A&M University, USA

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15 **Prevalence and type distribution of high-risk human papillomavirus in patients with Cervical Cancer: A population-based study**
Ashrafi G. Hossein, Kingston University, UK

14:15-14:35 **Cancer gene somatic mutation detection - A Tool for Personalized Cancer Therapy**
Michael J. Powell, DiaCarta, Inc., USA

14:35-14:55 **Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer**
Michela Zanardi, ASLTO2 SAN Giovanni Bosco Hospital, Italy

14:55-15:15 **Biological effects of therapeutic siRNA against TMPRSS2-ERG fusion oncogene for the treatment of prostate cancer**
Giorgia Urbinati, Institut Gustave Roussy, France

15:15-15:35 **The inhibition of breast cancer cell metastasis by anti-ErbB2 humanized antibody chA21 with a new recognition epitope**
Guodong Shen, Anhui Provincial Hospital, China

15:35-15:55 **Secretomic analysis reveals that alpha-actinin 4 induces cell migration and invasion and is a serological indicator of lung adenocarcinoma**
Pao-Chi Liao, National Cheng Kung University, Taiwan

15:55-16:15 **HPV Vaccination programs have not been demonstrated to be cost-effective in countries with comprehensive Pap screening and surgery**
Judy Wilyman, University of Wollongong, Australia

Coffee Break 16:15-16:30 @ Sierra Foyer

16:30-16:50 **Apatone® induces autoschizic cell death in human bladder cancer cells**
Karen McGuire, The Apatone Development Center, USA

16:50-17:10 **Nanodrug design and methods of activation for cancer therapy**
Renat R. Letfullin, Rose-Hulman Institute of Technology, USA

17:10-17:30 **Targeting microtubules in cancer Research: Application of computational simulations in developing novel chemotherapeutic agents**
Laleh Alisaraie, Memorial University of Newfoundland, Canada

17:30-17:50 **Radiolabeled nanoparticles for diagnostic purposes: Focus on cancer**
Andre Luis Branco de Barros, Federal University of Minas Gerais, Brazil

17:50-18:10 **High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy**
Wei Wang, Anhui Medical University, China

18:10-18:30 **Therapeutic and diagnostic formulations for the treatment of skin and endoscopic accessible cancers**
Jayakumar Rajadas, Stanford University School of Medicine, USA

18:30-18:50 **Hyperdiploid tumors as a driving force in genomic instability**
Roland B Sennerstam, Karolinska Hospital, Sweden

18:50-19:10 **Diagnostic and prognostic value of UHRF1 in breast cancer patients**
Feng Yan, Jiangsu Cancer Hospital & Nanjing Medical University Cancer Hospital, China

19:10-20:10 Cocktails Sponsored by **Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer**

Muir Woods

Track 3: Organ-Specific Cancers, Cancer Genetics, Drug Development and Diagnostics

Session Chair: Anupam Bishayee, American University of Health Sciences, USA

Session Co-Chair: James M. Jamison, Summa Health System, Saint Thomas Hospital, USA

Session Introduction

11:35-11:55 **Stromal androgen receptor in prostate cancer**
Peng Lee, New York University Langone Medical Center, USA

11:55-12:15 **The *In Vitro, In Vivo* and clinical activity of Apatone® against prostate cancer**
James M. Jamison, Summa Health System, Saint Thomas Hospital, USA

12:15-12:35 **Kaiso as prognosis marker of patients with Chronic myeloid leukemia**
Jaime Cofre, Santa Catarina University, Brazil

12:35-12:55 **Cancer prevention and treatment by natural products: Current evidence and future opportunities**
Anupam Bishayee, American University of Health Sciences, USA

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15 **Components of a successful population based cervical cancer screening programme for rural India: An evidence based practice implementation research in low-resource settings**
Rita Isaac, Christian Medical College, India

14:15-14:35 **Development of multi-pathway inhibitor screening system to combat the existing combinations of signaling dysregulations in gastric cancer**
Kumaresan Ganesan, Madurai Kamaraj University, India

14:35-14:55 **A cancer piggy-back screen to investigate whether changes in epigenetic state drive cancer growth**
Harten SK, Queensland Institute of Medical Research, Australia

14:55-15:15 **The role of integrated Positron Emission Tomography - Computed Tomography (PET-CT) imaging system in colorectal carcinoma**
Abdul Jalil Nordin, Universiti Putra Malaysia, Malaysia

15:15-15:35 **Evaluation of anti-cancer activity of survivin siRNA delivered by polyethylene-glycol liposomes in k562-bearing xenograft**
Suoqin Tang, Chinese PLA General Hospital, China

15:35-15:55 **Dissecting molecular networks of leptin in breast cancer: Complexities and opportunities**
Dipali Sharma, Sidney Kimmel Comprehensive Cancer Center, USA

Coffee Break 15:55-16:10 @ Sierra Foyer

16:10-17:30 **Poster Presentations @ Monterey**

18:50-19:50 Cocktails Sponsored by **Journal of Carcinogenesis & Mutagenesis @ Siersa Foyer**

Day 3 October 23, 2013

Sierra Ballroom

Track 8: Tumor Science
Track 9: Novel Approaches to Cancer Therapeutics

Session Chair: Kun Ping Lu, Harvard Medical School, Boston, USA

Session Co-Chair: Porunelloor A. Mathew, University of North Texas Health Science Center, USA

Session Introduction

09:00-09:20 **A new etiology for Prostate cancer and BPH - The pelvic floor**
Panikar Wadhera, Brooklyn hospital center, USA

09:20-09:40 **Comparing the effectiveness of craniofacial and endoscopic surgical approaches for the treatment of ethmoidsinonasal tumors**
Anisha R. Kumar, Stanford University School of Medicine, USA

09:40-10:00 **Rosemary extract enhances 5-fluoracil antitumor effect and overcomes resistance to the drug: New complementary approach for colon cancer therapy**
Ana Ramírez de Molina, IMDEA Food Institute, Spain

10:00-10:20 **Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents**
Bill E. Cham, Australasian Institute of Medical Research, Australia

10:20-10:40 **Title:Moving Forward with an Immunotherapy for the Prevention of Breast Cancer Recurrence**
Thomas Kieber-Emmons, University of Arkansas for Medical Sciences, USA

Coffee Break 10:40-10:55 @ Sierra Foyer

10:55-11:15 **Natural killer cell receptors and targeted immunotherapy for cancer**
Porunelloor A. Mathew, University of North Texas Health Science Center, USA

11:15-11:35 **The unique proline isomerase Pin1: A novel drug target acting on numerous key cancer-driving pathways**
Kun Ping Lu, Harvard Medical School, Boston, USA

11:35-11:55 **Inflammatory events influencing the chemical induced-squamous cell carcinoma**
Thais Helena Gasparoto, University of Sao Paulo, Brazil

11:55-12:15 **Evaluation of anticancer effects of Avelos latex (Euphorbia tirucalli), across the tumor clones detection test (warts) in Drosophila melanogaster**
Elcio Moreira Alves, University Center of Patos de Minas, Brazil

12:15-12:35 **Molecular players of DNA damage response in human malignancies**
Stefania Staibano, University of Neples Federico II, Italy

12:35-12:55 **Significance of antigen receptors in the innate immunity of cancer cells**
Gregory Lee, University of British Columbia, Canada

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15 **Analysis of leukemic stem cell populations comparing NPM1wt and NPM1mut AML patients and potential therapeutic targets**
Vanessa Schneider, University of Ulm, Germany

14:15-14:35 **Inhibitors of the histone methylase EZH2, a new anti-tumoral therapy?**
Catherine Bauge, Université de Caen Basse-Normandie, France

14:35-14:55 **Hadrontherapy, a new hope against radio- and chimio-resistant tumors**
Karim Boumediene, University of Caen, France

14:55-15:15 **The risk of excesive vaccinations in the medullary thyroid Adenocarcinoma**
Manuela Stoicescu, University of Oradea, Romania

15:15-15:35 **Hypoxic signature and cancer stem cell marker expression as tumor biology predictors**
Francesco Merolla, University "Federico II" of Naples, Italy

15:35-15:55 **MicroRNA miR-150 Contributes to the Proficiency of B-cell Receptor Signaling (BCR) in Malignant B cells**
Marek Mraz, Masaryk University, Czech Republic

Coffee Break 15:55-16:10 @ Sierra Foyer

16:10-16:30 **Oncothermia-Nano-heating paradigm**
Oliver Szasz, St.István University, Hungary

16:30-16:50 **NF-kB signaling in B-cell malignancies**
Sivakumar Vallabhapurapu, University of Cincinnati, USA

16:50-17:10 **The role of centrosomal protein TAX1BP2 in the pathogenesis of hepatocellular carcinoma**
Yick-Pang Ching, The University of Hong Kong, SAR China

Muir Woods

Track 4: Carcinogenesis & Mutagenesis and OMICS in Cancer Research
Track 6: Anti-Cancer Drug Discovery and Development

Session Chair: Samir A. Farghaly, The Weill Medical College of Cornell University, USA

Session Introduction

09:00-09:20 **Factors that promote malignancy and factors that inhibit malignancy without side effects**
Yoshiaki Omura, New York Medical College, USA

09:20-09:40 **Physical activity changes the reaction of circulating phagocytes to antineoplastic drug NSC631570**
Larysa Skivka, Taras Shevchenko National University of Kyiv, Ukraine

09:40-10:00 **siRNA formulated with tumor targeting scfv modified lph nanoparticles as possible therapy for metastaic epithelial ovarian cancer**
Samir A. Farghaly, The Weill Medical College of Cornell University, USA

10:00-10:20 **A novel genetic-based therapeutic platform for eradicating metastatic cancer**
Karli Rosner, Wayne State University, USA

10:20-10:40 **Synthesis and anticancer screening studies of indole-based piperazine derivatives**
Mine Yarim, Yeditepe University, Turkey

Coffee Break 10:40-10:55 @ Sierra Foyer

10:55-11:15 **The antitumor effect of a polysaccharide from Strongylocentrotus nudus eggs (SEP) is mediated by stimulating cytotoxic lymphocytes in vivo**
Mengyun Ke, China Pharmaceutical University, PR China

11:15-11:35 **Newcompouds of ruthenium present potencial of treatment for cancer**
Elisangela de Paula Silveira Lacerda, Federal University of Goias, Brazil

11:35-11:55 **Creating a new paradigm for cancer-based clinical trials by leveraging clinical and molecular data**
David A. Fenstermacher, Virginia Commonwealth University, USA

11:55-12:15 **Synthesis and anticancer screening studies of benzhydrylpiperazine derivatives**
E. Ece Gurdal, Yeditepe University, Istanbul, Turkey

12:15-12:35 **Measurement of DNA repair enzymes as cancer biomarkers**
Miral Dizdaroglu, National Institute of Standards and Technology, USA

12:35-12:55 **Polyploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors**
Angus Harding, The Diamantina Institute, Australia

Lunch Break 12:55-13:55 @ Tiburon/ Sausalito

13:55-14:15 **Cancer - Could be cured?**
Jozef Oleksyszyn, Wroclaw University of Technology, Poland

14:15-14:35 **Colloidal or silver nanoparticles reduce the growth of B16F10 melanoma tumors**
Franco-Molina M. A, Autonomous University of Nuevo Leon, Mexico

14:35-14:55 **ONC1-13B - New effective antiandrogen for the treatment of prostate and breast cancer**
Ruben N. Karapetian, Chemical Diversity Research Institute, Russia

14:55-15:15 **Phenethylisothiocyanate: A potential anti-cancer agent from watercress**
Ahmad Faizal Abdull Razis, Food Safety Research Centre (FOSREC), Malaysia

15:15-15:35 **Effect of calcium ions on neuroblastoma differentiation**
Priti Tiwari, Rutgers, The State University of New Jersey, USA

15:35-15:55 **The anti-tumor activities of a type I ribosome-inactivating protein, trichosanthin, and its toxic mechanism on lymphoma cells**
O. Sha, University of Shenzhen, China

15:55-16:15 **Development and characterization of transferrin modified artemether lipid nanospheres as a potent anticancer delivery system**
Eltayeb Suliman Elamin, China pharmaceutical university, China

Coffee Break 16:15-16:30 @ Sierra Foyer

Bookmark your dates

OMICS Group Conferences
Accelerating Scientific Discovery

4th World Congress on
Cancer Science & Therapy
October 20-22, 2014 Chicago, USA

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
omicsonline@omicsonline.com

OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
omicsonline@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, AP, INDIA
Ph: 040-40131823, 040-47482222
omicsgroup@omicsgroup.org

Toll free
USA & Canada: 1-800-216-6499
Australia: 1-800-651-097
Europe: 0805-080048